联合鉴定血清中的三种 lncRNA 作为乙型肝炎病毒相关肝细胞癌

StephenW

联合鉴定血清中的三种 lncRNA 作为乙型肝炎病毒相关肝细胞癌的有效诊断和预后生物标志物
彭福 1 , 龚斌斌 2 , 李慧明 1 , 青罗 1 , 黄子坤 1 , 仁峰山 3 , 李俊明 1 , 闫少英 1
隶属关系
隶属关系

    1
    【作者单位】： 江西省南昌市南昌大学第一附属医院临床检验科;
    2
    【作者单位】： 南昌大学第一附属医院泌尿外科;
    3
    【作者单位】： 南昌大学第一附属医院普外科;

    PMID：35802466 DOI：10.1002/ijc.34201

抽象的

乙型肝炎病毒相关肝细胞癌（HBV-related HCC）是一种常见的高侵袭性恶性肿瘤，死亡率高。本研究旨在确定 HBV 相关 HCC 的有效诊断和预后生物标志物。利用癌症基因组图谱（TCGA）数据库的 HBV 相关 HCC RNA 测序数据，鉴定了 159 个在 HBV 相关 HCC 和癌旁正常样本之间差异表达的长链非编码 RNA（lncRNA），最终评估了 12 个 lncRNA进行更深入的研究。分类分析开发了 AC005332.5、ELF3-AS1 和 LINC00665 的三个 lncRNA 特征，其 AUC（曲线下面积）值为 0.913（95% CI：0.8610-0.9665）和在验证患者中得到验证。 AC005332.5、ELF3-AS1和LINC00665的表达水平随着肿瘤分期或分级的不同而发生显着变化。生存分析显示，AC005332.5、ELF3-AS1和LINC00665与总生存期预后高度相关。此外，正如多变量 Cox 风险分析中所建议的那样，lncRNA 签名产生了统计显着性，可以独立于验证患者的其他临床变量预测临床结果。总之，AC005332.5、ELF3-AS1 和 LINC00665 的三个 lncRNA 特征可作为 HBV 相关 HCC 的优秀诊断生物标志物和 HBV 相关 HCC 患者的潜在预后意义。本文受版权保护。版权所有。

关键词：乙肝；生物标志物；诊断;肝细胞癌; lncRNA；预后。

本文受版权保护。版权所有。

StephenW

Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma
Peng Fu  1 , Binbin Gong  2 , Huiming Li  1 , Qing Luo  1 , Zikun Huang  1 , Renfeng Shan  3 , Junming Li  1 , Shaoying Yan  1
Affiliations
Affiliations

    1
    Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
    2
    Department of Urology, The First Afliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
    3
    Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

    PMID: 35802466 DOI: 10.1002/ijc.34201

Abstract

Hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) is a common, highly invasive malignant tumor associated with a high mortality rate. This study aimed to identify the effective diagnostic and prognostic biomarkers for HBV-related HCC. With HBV-related HCC RNA-sequencing data of The Cancer Genome Atlas (TCGA) database, 159 differentially expressed long non-coding RNAs (lncRNAs) between HBV-related HCC and para-carcinoma normal samples were identified, and 12 lncRNAs were eventually assessed for deeper research. Classification analysis developed a three-lncRNA signature of AC005332.5, ELF3-AS1, and LINC00665, which was demonstrated to be the most discriminatory with an AUC (Area Under the Curve) value of 0.913 (95% CI: 0.8610-0.9665) and verified in validation patients. The expression levels of AC005332.5, ELF3-AS1, and LINC00665 were significantly changed with different tumor stages or grades. Survival analysis revealed that AC005332.5, ELF3-AS1, and LINC00665 were highly associated with the prognosis of overall survival. Additionally, the lncRNA signature yielded statistical significance to predict clinical outcomes independently from other clinical variables in validation patients, as suggested in the multivariate Cox hazards analysis. Conclusively, a three-lncRNA signature of AC005332.5, ELF3-AS1, and LINC00665 may serve as an excellent diagnostic biomarker for HBV-related HCC and potential prognostic significance for HBV-related HCC sufferers. This article is protected by copyright. All rights reserved.

Keywords: HBV; biomarker; diagnosis; hepatocellular carcinoma; lncRNA; prognosis.

This article is protected by copyright. All rights reserved.